New polling shows Americans are sounding the alarm on the TRIPS IP waiver
Last week, the Biden administration announced support for a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which could lead to the removal of intellectual property protections for manufacturers of COVID-19 vaccines and treatments – a move some have suggested will speed global access in countries devastated by recent surges.  (Source: The Catalyst)
Source: The Catalyst - May 14, 2021 Category: Pharmaceuticals Authors: Cynthia Hicks Tags: Patents Intellectual Property Trade COVID-19 Source Type: news

The Biden Administration allows politics to upend a pragmatic pandemic response
Last week, the Biden Administration announced that it will support a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which would waive intellectual property (IP) protections for COVID-19 vaccines. Not only will this policydo nothing to help save lives globally, it could have a damaging impact for American patients.  (Source: The Catalyst)
Source: The Catalyst - May 14, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Patents Intellectual Property Trade COVID-19 Source Type: news

The ABCs (and Ds) of Medicare
For nearly 60 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans with certain medical needs. Medicare has many different programs, all named with different letters of the alphabet, so it can often feel confusing. With Medicare increasingly in the news, clarity around how it works and what types of health care it covers is important. We ’re here to break it down and share the basics about the different parts of Medicare:  (Source: The Catalyst)
Source: The Catalyst - May 13, 2021 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Part D Medicare Part B Source Type: news

Four solutions Americans support to make health care more affordable
Health care costs and affordability remain a major challenge for most Americans, even among those with insurance. According to aMarch Gallup poll, nearly one-in-five (18%) U.S. adults report that if they needed access to quality health care today, they would be unable to pay for it. The arrival of the COVID-19 crisis has only underscored the challenges facing patients, demonstrating that Americans are in need of a more affordable solution.  (Source: The Catalyst)
Source: The Catalyst - May 13, 2021 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Policy Solutions Polling Proactive Agenda Source Type: news

The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - May 12, 2021 Category: Pharmaceuticals Authors: Guest Contributor Tags: FDA Equity Proactive Agenda Source Type: news

New report demonstrates development of new medicines relies on private sector expertise and investment
America ’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. Critical to this ecosystem is the working relationship between industry and government agencies like the National Institutes of Health (NIH), academic medical centers and community-based research sites to further the translation of basic research into important medical products.  (Source: The Catalyst)
Source: The Catalyst - May 10, 2021 Category: Pharmaceuticals Authors: John Corea Tags: Research and Development Intellectual Property Drug Cost Source Type: news

PhRMA CAREs Grant request for proposals:  Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - May 6, 2021 Category: Pharmaceuticals Authors: Guest Contributor Tags: Vaccines COVID-19 Health Equity Source Type: news

A conversation with Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in communities of color
The COVID-19 pandemic exposed and often exacerbated the significant systemic health inequities that underserved communities have faced for many years. Black Americans have been particularly affected by these inequalities. These inequities and resulting disparities foster mistrust and contribute to vaccine hesitancy. (Source: The Catalyst)
Source: The Catalyst - May 5, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Equity Source Type: news

American leadership on innovation policy is essential to global health progress
Over the last year, the world has witnessed the importance of strong innovation policies as intellectual property protection and market access policies facilitated the research, development and distribution ofCOVID-19 diagnostics, treatments and vaccines. Innovative medicines are now making their way to patients around the world, demonstrating remarkableprogress andcollaboration at a scale that was unimaginable at the start of the pandemic, including more than 200 manufacturing and other partnerships to date. (Source: The Catalyst)
Source: The Catalyst - May 4, 2021 Category: Pharmaceuticals Authors: Ernest Kawka Tags: Intellectual Property Trade COVID-19 Source Type: news

Reflecting on Mental Health Awareness Month
As communities around the world continue to grapple with the impact of COVID-19, the importance of furthering our understanding of the impact on our mental health is undeniable. (Source: The Catalyst)
Source: The Catalyst - May 4, 2021 Category: Pharmaceuticals Tags: Research and Development Mental Illness Coronavirus Source Type: news

H.R. 3 threatens access to medicines, future innovation and American jobs
In the last election, voters made clear that they want quality, affordable health coverage that works when they need it and lower out-of-pocket costs for medicines. And we can achieve those goals, but the drug pricing plan known as H.R. 3 is not the answer. If implemented, it could have devastating consequences for patients ’ access to medicines, future innovation and American jobs. Put simply, H.R. 3 is the wrong approach for both patients and the U.S. health care system. Here are some reasons why: (Source: The Catalyst)
Source: The Catalyst - May 4, 2021 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Policy Solutions International Reference Pricing Proactive Agenda Source Type: news

New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging
The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened by a health crisis on the rise: antimicrobial resistance (AMR). AMR affects at least 3 million Americans and results in 48,000 U.S. deaths annually. The World Bank Group ’s 2017 report on drug-resistant infections estimates that unless action is taken, AMR globally could take 10 million lives annually by 2050, a higher toll than from cancer. If we fail to address the crisis, many modern medical advances that depend on antibi...
Source: The Catalyst - April 29, 2021 Category: Pharmaceuticals Tags: Medicines in Development Research and Development & D Focus Antimicrobial Resistance Source Type: news

New data from insurers show detriments of copay accumulator adjustment programs
Commercial health insurers are starting to admit what the biopharmaceutical research industry has been warning for some time: copay accumulator adjustment programs hurt patient outcomes and shift costs onto patients at the pharmacy counter. Those are some of the key findings from two new surveys that help demonstrate why these programs don ’t serve the best interests of patients. (Source: The Catalyst)
Source: The Catalyst - April 28, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Out-of-Pocket Costs Let's Talk About Cost Source Type: news

Patient safety is at the heart of COVID-19 vaccine R & D
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is continuingworking around the clock to research, develop and manufacture vaccines to prevent infection. To date, substantial progress has been made in vaccinating Americans with COVID-19 vaccines that have been granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA). (Source: The Catalyst)
Source: The Catalyst - April 26, 2021 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development Vaccines Coronavirus Source Type: news

Data shows that Americans are relying on vaccines to get us through the pandemic
As we continue to combat the pandemic, America ’s biopharmaceutical industry is working around the clock inunprecedented partnerships to manufacture COVID-19 vaccines, reaching billions of doses by the end of the year. Vaccination rates and willingness to receive a vaccine among Americans are also at a high, wherehalf of all adults in the U.S. have received at least one dose of the COVID-19 vaccine. (Source: The Catalyst)
Source: The Catalyst - April 22, 2021 Category: Pharmaceuticals Authors: Mark Keida Tags: Vaccines Polling Source Type: news

West Virginia becomes the first state to lower patient costs by sharing the savings
In a historic moment for patient affordability, last week West Virginia became the first state in the nation to adopt ground-breaking legislation, HB2263,requiring insurers and their PBMs to share the savings they negotiate on medicines directly with patients. (Source: The Catalyst)
Source: The Catalyst - April 20, 2021 Category: Pharmaceuticals Authors: Scott LaGanga Tags: Drug Cost Out-of-Pocket Costs Source Type: news

What they are saying: Experts highlight the importance of IP in recent NIST proposal comments
Strong, reliable, and clearly defined intellectual property (IP) protections are the foundation of America ’s robust innovation ecosystem that patients across the globe rely on for the research and development of new cures and treatments. Those protections were reinforced with the passage of the Bayh-Dole Act in 1980, a bipartisan piece of legislation that established a clearer framework for public-pri vate partnerships. Recently, the National Institute of Standards and Technology (NIST) accepted comments on the proposed rulemaking as it pertains to implementing parts of the Bayh-Dole Act. (Source: The Catalyst)
Source: The Catalyst - April 20, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Source Type: news

PhRMA member companies share how they are improving clinical trial diversity
As part of the biopharmaceutical industry ’sefforts to improve health outcomes for patients in underserved communities, PhRMA member companies are identifying ways to improve clinical trial diversity and reduce barriers to participation for Black and Brown communities. As these efforts continue to take shape, our industry is developing potential best practices and key learnings that we are excited to share as part of our effort to tackle these challenges head on. (Source: The Catalyst)
Source: The Catalyst - April 14, 2021 Category: Pharmaceuticals Authors: Dr. Freda Lewis-Hall Tags: Health Equity Source Type: news

Our three-part approach to build a better health care system
On April 3, more thanfour million Americans received a COVID-19 vaccine — the largest single-day vaccination event in human history. For innovators across the pharmaceutical industry, these moments make the years — sometimes decades — of painstaking trial and error worth it. (Source: The Catalyst)
Source: The Catalyst - April 13, 2021 Category: Pharmaceuticals Tags: Proactive Agenda Source Type: news

ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
America ’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. The ongoing development of new, life-saving and life-improving medicines, including those forCOVID-19, would not be possible without the robust investment, scientific expertise and manufacturing capabilities from biopharmaceutical research companies. (Source: The Catalyst)
Source: The Catalyst - April 12, 2021 Category: Pharmaceuticals Tags: R & D Focus COVID-19 Source Type: news

Diversifying clinical trials and fighting disease requires equity and trust
The COVID-19 pandemic has left no person unaffected, but Black Americans have been disproportionately impacted. Black adults are nearlyfour times more likely to be hospitalized from the virus and nearlythree times more likely to die from the virus than their white counterparts. At the same time, recent polls highlight COVID-19 vaccine hesitancy within Black communities. In fact, only one in four Black Americans (24%) plan to get the vaccine compared to other racial and ethnic groups, and Black Americans are significantly trailing invaccination rates. (Source: The Catalyst)
Source: The Catalyst - April 12, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Equity Source Type: news

Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections
Earlier this week PhRMA submittedcomments to the National Institute of Standards and Technology (NIST) regarding the proposed rulemaking on implementing regulations of the Bayh-Dole Act. Passed in 1980, the Bayh-Dole Act was a landmark piece of bipartisan legislation that established a uniform framework across the federal government to encourage technology transfer between universities and the private sector that has facilitated timely and efficient commercialization of early-stage research. Since its passage, it has fueled unprecedented innovation across the United States. (Source: The Catalyst)
Source: The Catalyst - April 9, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Intellectual Property Source Type: news

Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis
This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. Outside of the novel coronavirus, major social issues have been brought to the forefront of public discourse. We understand that systematic racism is as real as any disease and our industry is not immune. We need to stand up to racism and injustice because failing to do so impacts our collective wellbeing. Our industry is committed to learning and leading us forward. (Source: The Catalyst)
Source: The Catalyst - March 31, 2021 Category: Pharmaceuticals Source Type: news

Data shows that  keeping a strong biopharmaceutical industry is important to Americans
The United States biopharmaceutical industry continues to innovate and discover critical solutions for our toughest health challenges such asthe COVID-19 pandemic. America ’s global leadership has not been by chance, but rather the result of a well-planned effort to facilitate innovation by incentivizing and protecting inventors and supporting collaboration between and among the public and private sectors. (Source: The Catalyst)
Source: The Catalyst - March 30, 2021 Category: Pharmaceuticals Authors: Mark Keida Source Type: news

New report demonstrates the growing importance of partnerships in advancing biomedical innovation
As we mark a full year since COVID-19 was declared a global pandemic, it ’s impossible to overstate the significance of collaborations. The unprecedented level of strategic collaborative efforts that have taken place across the biopharmaceutical ecosystem have been central to efforts to ensure efficient development, manufacture and distribution of critical COVID-19 vac cines and treatments. The coronavirus outbreak has brought new attention to the importance of these innovative cross-stakeholder partnerships. Anew report from PhRMA looks broadly at the collaborative ecosystem and illustrates biopharmaceutical industr...
Source: The Catalyst - March 24, 2021 Category: Pharmaceuticals Authors: Abigail Lore Source Type: news

Cross-country comparisons of medicine prices are like comparing apples to oranges
Looking at differences in medicine prices between the United States and other countries can be misleading, often ignoring the complexities in the U.S. system and the repercussions of other countries ’ reliance on government price-setting policies. As the discussion unfolds, here are five often overlooked facts that are critically important to keep in mind. (Source: The Catalyst)
Source: The Catalyst - March 22, 2021 Category: Pharmaceuticals Source Type: news

Building confidence in the COVID-19 vaccine through education
Throughout the COVID-19 vaccine research and development process, the biopharmaceutical industry hasworked to upholdthehighest standards of research, clinical testing and manufacturing. (Source: The Catalyst)
Source: The Catalyst - March 22, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Vaccines COVID-19 Source Type: news

ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy
On January 19, 2021 – the last full day of the Trump administration – CMS released a Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This model would provide “formulary flexibility” by exempting participating Part D plans from some of Part D’s formulary coverage requi rements. These requirements include rules for the six “protected classes” and the two drugs per class requirements. (Source: The Catalyst)
Source: The Catalyst - March 11, 2021 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Part D Medicare Source Type: news

Getting the 340B program back on track in 2021
As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have been disproportionately impacted by COVID-19. That ’s why it has never been more important for policymakers to ensure federal programs, like the 340B program, are benefiting the safety net that serves our underserved communities. Unfortunately, nearly three decades after it was originally created, the 340B program no longer resembles its original mission. (Source: The Catalyst)
Source: The Catalyst - March 10, 2021 Category: Pharmaceuticals Tags: Access Patients 340B Hospitals Source Type: news

ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have madeunprecedented progress in advancing treatments and vaccines to help fight COVID-19. At this time, three vaccines and several treatments have received emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) with one treatment receiving FDA approval. Additional candidates under investigation have also shown promise. (Source: The Catalyst)
Source: The Catalyst - March 8, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Source Type: news

Intellectual property is the key to vaccine development, manufacturing and technology sharing
Earlier today, 31 PhRMA board members signed aletterto President Joe Biden applauding the Administration ’s accelerating COVID-19 vaccine rollout, but also warning against efforts to undermine American intellectual property andinnovation-dependent manufacturing jobs. (Source: The Catalyst)
Source: The Catalyst - March 5, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Intellectual Property Vaccines Manufacturing Coronavirus Source Type: news

Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
Last week,PhRMA submitted comments to the United States Patent and Trademark Office (USPTO) in response to a request for comments on the National Strategy for Expanding American Innovation. PhRMA ’s comments focus on the types of initiatives and efforts that could be included in a national strategy to make the innovation ecosystem more diverse and inclusive and that build on the breadth and depth of biopharmaceutical initiatives that both bolster theSTEM talent pipeline and support D&I in the workplace. This comment letter follows therelease of a PhRMA report rich with insights into how PhRMA member companies are...
Source: The Catalyst - March 5, 2021 Category: Pharmaceuticals Authors: Abigail Lore Tags: Research and Development PhRMA Member Company Equity Source Type: news

How industry collaboration and partnerships are supporting COVID-19 vaccine manufacturing
Across the industry, biopharmaceutical companies areworking around the clock to meet the demands of COVID-19 vaccine manufacturing. Companies are working to source needed raw materials and other supplies and increasing manufacturing capacity to get COVID-19 vaccine shots in as many arms as possible. Even prior to knowing the efficacy of particular vaccine candidates, companies have proactively been seeking to increase their own manufacturing capabilities as well as collaborate with other manufacturers who shared available capacity to support efforts to increase production. These partnerships have been key so that as safety...
Source: The Catalyst - March 4, 2021 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development Vaccines Manufacturing Coronavirus Source Type: news

Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter
A new study published inHealth Affairs finds that for nearly 40% of commercially insured patients, half of their annual out-of-pocket expenses for medical treatments come from just one hospital, doctor or pharmacy visit. (Source: The Catalyst)
Source: The Catalyst - March 2, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Out-of-Pocket Costs Let's Talk About Cost Source Type: news

Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. (Source: The Catalyst)
Source: The Catalyst - February 24, 2021 Category: Pharmaceuticals Tags: PhRMA Member Company Vaccines Coronavirus Source Type: news

ICYMI: Report provides actional recommendations to strengthen America ’s preparedness and future health crises response
As America ’s biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen America’s preparedness and future health care crises response. (Source: The Catalyst)
Source: The Catalyst - February 22, 2021 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Coronavirus Antimicrobial Resistance Pandemic Preparedness Source Type: news

ICYMI: Report provides actionable recommendations to strengthen America ’s preparedness and future health crises response
As America ’s biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen America’s preparedness and future health care crises response. (Source: The Catalyst)
Source: The Catalyst - February 22, 2021 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Coronavirus Antimicrobial Resistance Pandemic Preparedness Source Type: news

Fighting variants of COVID-19
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop and manufacture safe and effective vaccines. To date, two vaccines have been granted Emergency Use Authorization (EUA) in the United States by the U.S. Food and Drug Administration (FDA). Another vaccine candidate has been submitted for an EUA and several others have made substantial progress in their clinical development programs. Meanwhile, Americans across the country have now started to be vaccinated. While this is a tremendous achievement, biopharmaceutical companies are n...
Source: The Catalyst - February 22, 2021 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development Vaccines Coronavirus Source Type: news

Key excerpts: PhRMA submits comments to keep the six protected classes protected
Earlier this month, PhRMAsubmitted comments to CMS regarding the Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This RFA was released on January 19, 2021 – the last full day of the Trump Administration. Since the inception of the Medicare Part D program, PhRMA has supported the Part D policy of protecting certain drug categories or classes in which patients require access to a broad range of treatments without unreasonable delay. The protected clas s policy offers valuable protections for vulnerable patients and PhRMA strenuously opposes any weakening of the formulary protec...
Source: The Catalyst - February 19, 2021 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Part D Medicare Source Type: news

Top five issues voters want addressed in the administration ’s first 100 days
When voters cast their ballots in the 2020 election, they made clear their focus on gettingCOVID-19 under control and fixing the economy. However, health care was still important to many voters, and in our review of public and PhRMA ’s national and “state battleground” exit polling, we learned voters were most worried about protecting pre-existing conditions protections and addressing rising out-of-pocket costs associated with worsening health coverage. (Source: The Catalyst)
Source: The Catalyst - February 18, 2021 Category: Pharmaceuticals Authors: Mark Keida Tags: Drug Cost Out-of-Pocket Costs Coronavirus Polling Source Type: news

The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
Strong and reliable IP protections – including patents – have supported America’s robust innovation ecosystem by promoting discovery, development, affordability and access to new treatments and cures. As our industry continues to expand vaccine production and deliver medicines to patients in need, reliable IP protections have b een critical in supporting multiple research and development and manufacturing ramp-ups on COVID-19 vaccines and therapeutics. Innovators need strong and reliable IP protections to research, develop and manufacture new therapeutics and vaccines that will improve patients’ liv...
Source: The Catalyst - February 12, 2021 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Intellectual Property IP Explained Coronavirus Source Type: news

Beyond output and employment: The impact of America ’s biopharmaceutical industry
Particularly in recent times, biopharmaceutical companies have become increasingly important to the American economy. But just how valuable are they? In the United States, these businesses support over 811,000 jobs and have sponsored more than 4,500 clinical trials. Impressive employment and output numbers, to be sure, but taken by themselves, these values don ’t tell the whole story. (Source: The Catalyst)
Source: The Catalyst - February 11, 2021 Category: Pharmaceuticals Authors: Ryan Garofalo Tags: Economic Impact Source Type: news

Lessons learned from COVID-19: The way we develop new medicines is changing
The COVID-19 pandemic has affected nearly every aspect of society, including the way scientists conduct the testing of medicines. (Source: The Catalyst)
Source: The Catalyst - February 10, 2021 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development & D Focus Coronavirus Source Type: news

Action needed to preserve the six protected classes
In the final hours of the previous Administration ’s time in office, the Center for Medicare& Medicaid Innovation (the Innovation Center) (CMMI) announced new changes for CY 2022 to an existing five-year Part D Payment Modernization Model. This model would provide “formulary flexibility” by exempting Part D plans in the Model from some of Part D’s normal formulary coverage requirements, including rules for the six “protected classes” and the two drugs per class requirement. This change would ultimately impact the most vulnerable patients, including those with cancer, mental illness, ...
Source: The Catalyst - February 3, 2021 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Cancer HIV/AIDS Part D Medicare Mental Illness Source Type: news

Insurers shift medicine costs to patients with severe chronic illnesses
For many patients with complex and chronic conditions, high out-of-pocket costs for medicines pose a significant challenge. Recent research revealed abroken insurance system that fails to help those who need care most. New resources further demonstrate how patients withasthma,diabetes,HIV andcancer can face high out-of-pocket costs due to insurance design. (Source: The Catalyst)
Source: The Catalyst - February 1, 2021 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Drug Cost Out-of-Pocket Costs Medicaid Let's Talk About Cost Source Type: news

Tennessee ’s Medicaid demonstration fails patients
Prior to its departure from office, the Trump Administration approved Tennessee ’s request for a demonstration to change how the state’s Medicaid program operates, and more importantly, how vulnerable patients access the health care they need. (Source: The Catalyst)
Source: The Catalyst - February 1, 2021 Category: Pharmaceuticals Authors: Hannah Loiacono Tags: Medicaid Source Type: news

Preserving U.S. innovation worldwide is more important than ever
The COVID-19 pandemic has spurredunprecedented levels of innovation within the biopharmaceutical industry to combat this urgent global health crisis. PhRMA member companies are collaborating with governments, academia, NGOs and one another and areworking around the clock to research, develop and deliverCOVID-19 vaccines and treatments. This swift action and collaboration is made possible because the United States protects and values innovation – which helped enable our industry to translate research into safe and effective products in less than a year that can end the pandemic. (Source: The Catalyst)
Source: The Catalyst - January 29, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Economic Impact Intellectual Property Trade Source Type: news

Growing trend: Increased vaccine confidence
According to researchers writing inThe Lancet, we need a majority of Americans to have the confidence to get vaccinated for COVID-19 if we are going to be effective in moving the United States toward population-level control of viral spread. As Dr. Anthony Fauci has noted, “If you have a vaccine that is highly effective and not enough people get vaccinated, you’re not going to realize the full, important effect of having a vaccine.” (Source: The Catalyst)
Source: The Catalyst - January 28, 2021 Category: Pharmaceuticals Authors: Mark Keida Tags: Vaccines Coronavirus Source Type: news

Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Our industry has committed itself to making our workplaces trusting places to have complex, and sometimes difficult, conversations about diversity and inclusion. (Source: The Catalyst)
Source: The Catalyst - January 28, 2021 Category: Pharmaceuticals Authors: Courtney Christian Tags: PhRMA Member Company Health Equity Source Type: news

The latest misleading “poll” on drug pricing
When a front group for insurers and drug cost middlemen promote a poll on drug pricing, everyone ’s immediate reaction should include a healthy dose of skepticism. The same is true for apollfrom the Campaign for Sustainable Rx Pricing, a group funded by the insurance lobby and pharmacy benefit managers – the same people who determine what patients pay at the pharmacy for prescription medicines. (Source: The Catalyst)
Source: The Catalyst - January 28, 2021 Category: Pharmaceuticals Authors: Brian Newell Tags: Out-of-Pocket Costs Source Type: news